1996 Oct 25;52(8):1147-54
It is feasible to double the capacity at Belgium to approximately 100 to 150 million vials per annum and Catalents Indiana facility will potentially produce 70 million vials. Furthermore, Henry said if Novo subsidized equipment upgrades and implemented operational efficiencies to the existing lines, it could increase capacity by 20% per annum
Preclinical models suggest that NRF2 activation enhances antioxidant enzyme expression, but human clinical evidence in FM is lacking (22, 23)
Also, the comparative effectiveness of GLP1 receptor agonists and SGLT2 inhibitors has been a growing interest, and several cohort studies with robust methodology have concluded comparable dementia risk between initiators of GLP1 receptor agonists and SGLT2 inhibitors [16, 25, 26]
Kawamoto EM, Vivar C, Camandola S
Disminuye el riesgo cardiovascular